Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?

References

• Guarner J. Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19. Am J Clin Pathol 2020;153:420–1.
   PubMed Web of Science ®Google Scholar
• COVID Live - Coronavirus Statistics - Worldometer. Available from: www.worldometers.info/coronavirus/ [last accessed 04 Apr 2022].
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, ‘Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)’. Available from: www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html [last accessed 04 Apr 2022].
   Google Scholar
• Bolcato G, Bissaro M, Pavan M, et al. Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir. Sci Rep 2020;10:20927.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.
   PubMed Web of Science ®Google Scholar
• Mani D, Wadhwani A, Krishnamurthy PT. Drug repurposing in antiviral research: a current scenario. J Young Pharm 2019;11:117–21.
   Web of Science ®Google Scholar
• Viveiros Rosa SG, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica 2020;44:e40.
   PubMed Web of Science ®Google Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect 2022;28:202–21.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 2021;21:83–100.
   PubMed Web of Science ®Google Scholar
• Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin Infect Dis 2021;73:2257–64.
   PubMed Web of Science ®Google Scholar
• Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program - Israel, December 2020-February 2021. MMWR Morb Mortal Wkly Rep 2021;70:326–8.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021;19:409–24.
   PubMed Web of Science ®Google Scholar
• Consortium TCM, et al. Open science discovery of oral non-covalent SARS-CoV-2 main protease inhibitor therapeutics. bioRxiv 2020.10.29.339317 2022
   Google Scholar
• Morris A, McCorkindale W, Consortium TCM, et al. Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model. Chem Commun 2021;57:5909–12.
   PubMed Web of Science ®Google Scholar
• Kokic G, Hillen HS, Tegunov D, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun 2021;12:1–7.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med 2020;383:1813–26.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970–5.
   PubMed Web of Science ®Google Scholar
• Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2021;21:1–13.
   PubMed Web of Science ®Google Scholar
• Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science 2021;374:1586–93.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022.
   Web of Science ®Google Scholar
• Temmam S, Vongphayloth K, Baquero E, et al. Bat coronaviruses related to SARS-CoV-2 and infectious for human cells. Nature 2022.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE), 2019.01; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2021. Available from: https://www.chemcomp.com/Research-Citing_MOE.htm.
   Google Scholar
• Xue X, Yang H, Shen W, et al. Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. J Mol Biol 2007;366:965–75.
   PubMed Web of Science ®Google Scholar
• Flynn JM, Samant N, Schneider-Nachum G, et al. Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. bioRxiv 2022.01.26.477860. 2022.
   Google Scholar
• Pavan M, Bolcato G, Bassani D, et al. Supervised molecular dynamics (SuMD) insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J Enzyme Inhib Med Chem 2021;36:1646–50.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Fang C, Zhang Q, et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell 2021:1–5.
   Web of Science ®Google Scholar
• Fornasier E, Macchia ML, Giachin G, et al. A new inactive conformation of SARS-CoV-2 main protease. Acta Crystallogr. Sect. D Struct. Biol 2022;78:363–78.
   Google Scholar
• Bassani D, Pavan M, Bolcato G, et al. Re-exploring the ability of common docking programs to correctly reproduce the binding modes of non-covalent inhibitors of SARS-CoV-2 protease Mpro. Pharmaceuticals 2022;15:180.
   Web of Science ®Google Scholar
• Bissaro M, Bolcato G, Pavan M, et al. Inspecting the mechanism of fragment hit binding on SARS‐CoV‐2 Mpro by using supervised molecular dynamics (SuMD) simulations. ChemMedChem 2021;16:2075–81.
   PubMed Web of Science ®Google Scholar
• Zhang C-H, Stone EA, Deshmukh M, et al. Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent Sci 2021;7:467–75.
   PubMed Web of Science ®Google Scholar
• Luttens A, Gullberg H, Abdurakhmanov E, et al. Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses. J Am Chem Soc 2022;144:2905–20.
   PubMed Web of Science ®Google Scholar
• Anand K, Palm GJ, Mesters JR, et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 2002;21:3213–24.
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300:1763–7.
   PubMed Web of Science ®Google Scholar
• Ho B-L, Cheng S-C, Shi L, et al. Critical assessment of the important residues involved in the dimerization and catalysis of MERS coronavirus main protease. PLoS One 2015;10:e0144865.
   PubMed Web of Science ®Google Scholar